MYRON Z. HOLUBIAK - 19 Sep 2025 Form 4 Insider Report for CITIUS ONCOLOGY, INC. (CTOR)

Role: Secretary, Director
Signature: /s/ Alexander M. Donaldson, by Power of Attorney
Issuer symbol: CTOR
Transactions as of: 19 Sep 2025
Transactions value $: $0
Form type: 4
Filing time: 23 Sep 2025, 16:10:26 UTC
Previous filing: 12 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
HOLUBIAK MYRON Z	Secretary, Director	C/O CITIUS ONCOLOGY, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD	/s/ Alexander M. Donaldson, by Power of Attorney	23 Sep 2025	0001199080

This filing has been restated, see here for the amended filing

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CTOR	Common Stock	Award	$0	+850K		$0.00	850K	19 Sep 2025	Direct	F1
transaction	CTOR	Common Stock	Award	$0	+100K		$0.00	100K	19 Sep 2025	See footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CTOR	Stock Option (Right to Buy)						300K	19 Sep 2025	Common Stock	300K	$1.07	Direct	F3
holding	CTOR	Stock Option (Right to Buy)						50K	19 Sep 2025	Common Stock	50K	$1.07	See footnote	F3, F4
holding	CTOR	Stock Option (Right to Buy)						1.5M	19 Sep 2025	Common Stock	1.5M	$2.15	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock awards granted on September 19, 2025. The shares will vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
F2	Represents restricted stock awards granted on September 19, 2025 to the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares.
F3	These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
F4	These options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares.
F5	These options vest over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.